IMPORTANT INFORMATION

  • CFTR.info is an online educational resource on the genetics of cystic fibrosis (CF) and the role of CF transmembrane conductance regulator (CFTR) in normal human physiology as well as in CF.
  • The information contained herein is intended for healthcare professionals working within the European Union (EU).
  • The content of this website has been developed independently by a group of CF healthcare professionals and is for general information purposes only.
  • All of the information about CFTR and CFTR modulators has been obtained from referenced sources and is in the public domain.
  • This website is not intended to promote or advocate a particular course of treatment or any specific drug, whether licensed or unlicensed, nor is it intended to imply or suggest that any drug be used for any purpose other than that which for which it is licensed in the EU.

ABBREVIATED TERMS & CONDITIONS

  • While we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information and related graphics, or products and treatments, contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
  • In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from, or in connection with, the use of this website.
  • Through this website you are able to link to other websites which are not under our control. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
  • Every effort is made to keep the website up and running smoothly. However, we take no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

Please see the full Terms & Conditions before using this website.

 

I have read and understood the above

About CF » Pathophysiology of CF » GastrointestinaI tract

GastrointestinaI tract

Pathogenesis

 

CFTR is present on the epithelial cells lining the gastrointestinal tract (GI). Defects in CFTR lead to reduced secretion of chloride and bicarbonate into the intestinal tract and hyperabsorption of water from the gut. This causes accumulation of viscous mucus and faecal material in the terminal ileum, caecum and ascending colon leading to obstruction by mucofaeculant material.1 In fact, up to 15% of  newborn babies with CF suffer from intestinal obstruction,2, 3 and up to 18% of adults suffer from a recurrent bowel obstruction known as distal intestinal obstructive syndrome (DIOS).4

Viscous mucus and faecal material often obstruct the GI in people with cystic fibrosis. This leads to nutrient malabsorption compounded by low duodenal pH, which is a consequence of pancreatic insufficiency
References
  1. Walker NM et al. J Pharmacol Exp Ther 2006;317:275–83
  2. Rowe SM & Clancy JP. Curr Opin Pediatr 2006;18:604–13
  3. Walkowiak J et al. Eur J Gastroenterol Hepatol 2008;20:157–60
  4. Dray X et al. Clin Gastroenterol Hepatol 2004;2:498–503